We are live on
!
Find out more
DM
Deerfield Management Portfolio holdings
AUM
$8.48B
1-Year Est. Return
99.04%
This Fund
S&P 500
This Quarter
Est. Return
-6.2%
1 Year Est. Return
+99.04%
3 Year Est. Return
+273.78%
5 Year Est. Return
+280.99%
10 Year Est. Return
+2,168.14%
AUM
$4.77B
AUM Growth
-$356M
(-7%)
Cap. Flow
-$1.35B
Cap. Flow
% of AUM
-28.26%
Top 10 Holdings %
Top 10 Hldgs %
39.93%
Holding
155
New
23
Increased
16
Reduced
21
Closed
28
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
DCPH
Deciphera Pharmaceuticals, Inc. Common Stock
DCPH
|
+$89.6M |
| 2 |
AdaptHealth
AHCO
|
+$49.8M |
| 3 |
ESPR
Esperion Therapeutics
ESPR
|
+$40M |
| 4 |
Xilio Therapeutics
XLO
|
+$36.7M |
| 5 |
FIGS
FIGS
|
+$27.3M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BDSI
BioDelivery Sciences International, Inc.
BDSI
|
+$30.8M |
| 2 |
Molina Healthcare
MOH
|
+$28.8M |
| 3 |
Cytokinetics
CYTK
|
+$28.1M |
| 4 |
XLRN
Acceleron Pharma
XLRN
|
+$25M |
| 5 |
Fate Therapeutics
FATE
|
+$21.5M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 62.96% |
| 2 | Financials | 1.4% |
| 3 | Consumer Discretionary | 0.48% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
26
Xilio Therapeutics
XLO
$58.4M
| $33.7M | 0.71% |
+153,862
| New | +$36.7M |
|
|
AERI
27
DELISTED
Aerie Pharmaceuticals
AERI
| $33M | 0.69% |
4,695,020
+1,718,000
| +58% | +$18M |
|
28
The Oncology Institute
TOI
$535M
| $32.1M | 0.67% |
3,296,107
-1,703,893
| -34% | -$15.1M |
|
29
Nuvation Bio
NUVB
$2.02B
| $30.4M | 0.64% |
3,577,233
| – | – |
|
|
SWTX
30
DELISTED
SpringWorks Therapeutics
SWTX
| $28M | 0.59% |
452,000
-58,673
| -11% | -$3.88M |
|
|
ESPR
31
DELISTED
Esperion Therapeutics
ESPR
| $25M | 0.52% |
+5,000,000
| New | +$40M |
|
32
BioCryst Pharmaceuticals
BCRX
$2.36B
| $23.4M | 0.49% |
1,686,140
+1,451,497
| +619% | +$19.2M |
|
|
VIVO
33
DELISTED
Meridian Bioscience Inc
VIVO
| $23M | 0.48% |
1,125,083
-938,000
| -45% | -$18M |
|
|
34
FIGS
FIGS
$1.72B
| $22.9M | 0.48% |
+829,707
| New | +$27.3M |
|
35
Pharvaris
PHVS
$2.44B
| $22.8M | 0.48% |
1,581,331
-27,140
| -2% | -$424K |
|
36
Revolution Medicines
RVMD
$39.6B
| $22.4M | 0.47% |
891,587
-674,125
| -43% | -$19M |
|
37
Brookdale Senior Living
BKD
$3.58B
| $22.1M | 0.46% |
4,274,808
-977,992
| -19% | -$6.1M |
|
38
Alector
ALEC
$167M
| $21.8M | 0.46% |
1,055,192
| – | – |
|
|
BLU
39
DELISTED
BELLUS Health Inc.
BLU
| $19.7M | 0.41% |
+2,449,000
| New | +$16.3M |
|
|
PROF
40
Profound Medical
PROF
$249M
| $19.2M | 0.4% |
1,713,797
+416,000
| +32% | +$5.2M |
|
41
Rhythm Pharmaceuticals
RYTM
$7.31B
| $18.6M | 0.39% |
1,867,467
-122,158
| -6% | -$1.37M |
|
42
Outset Medical
OM
$77.9M
| $18.5M | 0.39% |
26,708
| – | – |
|
|
NVRO
43
DELISTED
NEVRO CORP.
NVRO
| $17.5M | 0.37% |
+216,000
| New | +$21.6M |
|
|
KNTE
44
DELISTED
Kinnate Biopharma Inc. Common Stock
KNTE
| $17.5M | 0.37% |
985,568
-42,940
| -4% | -$906K |
|
45
CALL
BridgeBio Pharma
BBIO
$15.9B
| $16.7M | 0.35% |
+1,000,000
| New | +$42.3M |
|
|
ONCR
46
DELISTED
Oncorus, Inc.
ONCR
| $16.6M | 0.35% |
3,148,977
| – | – |
|
|
TERN
47
DELISTED
Terns Pharmaceuticals
TERN
| $16.6M | 0.35% |
2,345,959
| – | – |
|
|
APLS
48
DELISTED
Apellis Pharmaceuticals
APLS
| $16.2M | 0.34% |
+343,213
| New | +$13.5M |
|
|
INZY
49
DELISTED
Inozyme Pharma
INZY
| $16M | 0.34% |
2,344,786
| – | – |
|
|
DALS
50
DELISTED
DA32 Life Science Tech Acquisition Corp. Class A Common Stock
DALS
| $15.7M | 0.33% |
1,600,000
| – | – |
|
Similar funds
FT
GRQ
AV
PCM
VA
QC
IC
NW
Deerfield Management's Q4 2021 Portfolio in Review
As of Q4 2021, Deerfield Management held 155 positions worth $4.77B, down 7% from $5.12B the previous quarter. Its ten largest holdings account for 40% of the portfolio.
Deerfield Management withdrew a net $1.35B in Q4 2021, closing 28 positions and reducing 21 holdings. Its most notable exit was Acceleron Pharma, an estimated $25M position sold in full.
By sector, the portfolio is most concentrated in Healthcare at 63% of assets, down from 66% a quarter earlier, followed by Financials and Consumer Discretionary.
Against the trend, Deerfield Management opened a new position in Esperion Therapeutics worth $25M.
- Deerfield Management's largest Q4 2021 buy was Esperion Therapeutics: 5,000,000 shares worth $25M.
- Deerfield Management added most to Deciphera Pharmaceuticals, Inc. Common Stock in Q4 2021, an estimated $89.6M increase.
- Deerfield Management's biggest Q4 2021 reduction was BioDelivery Sciences International, Inc., cutting an estimated $30.8M.
- Deerfield Management fully exited Acceleron Pharma in Q4 2021, selling an estimated $25M.
- Deerfield Management's ten largest holdings make up 40% of its $4.77B portfolio in Q4 2021.
- Deerfield Management opened 23 new positions and closed 28 in Q4 2021.
- Deerfield Management's portfolio value fell 7% quarter-over-quarter to $4.77B.
Based on Deerfield Management's 13F filing for Q4 2021, filed 14 Feb 2022.